NORCROSS, Ga., Oct. 1 /PRNewswire-FirstCall/ -- Immucor, Inc. (Nasdaq: BLUD), a global leader in providing automated instrument-reagent systems to the blood transfusion industry, today reported financial results for its fiscal 2010 first quarter ended August 31, 2009.
"Despite the economy, we continue to generate revenue, earnings and cash flow growth due to the needs-based aspect of our business and our focus on automation that improves blood bank operations," stated Dr. Gioacchino De Chirico, Immucor's President and Chief Executive Officer.
Selected Product Revenue and Gross Margin ($ amounts in thousands) Revenue Fiscal Q1 2010 Fiscal Q1 2009 Growth -------------- -------------- ------ Gross Gross Revenue Margin Revenue Margin $ % ------- -------- ------- -------- - - Traditional reagents $54,719 76.1% $49,272 78.7% $5,447 11% Capture reagents 18,303 83.3% 15,174 86.7% 3,129 21% Instruments 9,292 32.0% 8,579 17.4% 713 8%
Consolidated revenue was $83.1 million in the current year quarter, an increase of approximately $9.9 million, or 14%, over the first quarter of fiscal 2009. Revenue in the quarter benefited from both price and volume contributions. Revenue in the quarter, as compared with the first quarter of fiscal 2009, was negatively impacted by approximately $1.7 million due to fluctuations in foreign currency exchange rates.
Consolidated gross margin was $59.7 million, or 71.9% of revenue, in the current year quarter compared with $53.4 million, or 73.0% of revenue, in the prior year quarter. During the current year quarter, gross margin was negatively impacted by the costs related to the Company's Quality Process Improvement Project. The Project's goal is to establish a world-class quality system while simultaneously addressing the deficiencies noted by the Food and Drug Administration in its June 2009 administrative action.
"We are making good progress on our Quality Process Improvement Project and continue to believe that our efforts will result in a world-class quality system," stated Dr. De Chirico. "We remain on track for the project to be completed by the end of our third quarter of fiscal 2010."
Operating expenses for the first fiscal quarter of 2010 increased by approximately $3.5 million, or 16%, over the prior year quarter primarily attributable to the BioArray acquisition.
Summary of Instrument Orders Q1 2010 Orders -------------- Cumulative Instrument N.A. (1) ROW(2) Total Orders (3) ---------- --------- -------- ------ --------- Echo 23 17 40 643 Galileo 0 14 14 651 (1) N.A. - North America (the U.S. and Canada) (2) ROW - all parts of the world other than the U.S. and Canada (3) Cumulative Orders - total orders received since the launch of the instrument
Of the cumulative orders since the instruments' launch, approximately 430 Echo orders and 614 Galileo orders were generating reagent revenue at their expected annualized run rate as of August 31, 2009, an increase of 70 Echo instruments and 18 Galileo instruments in the fiscal first quarter.
"We have seen a lengthening of sales cycles for the Echo in fiscal 2010 and now believe that we will generate 280 to 320 Echo orders compared with our previous expectations of 320 to 350 orders in fiscal 2010," stated Dr. De Chirico. "We have strong Echo pipelines and continue to believe in the opportunity for Echo, which is targeted at small- to medium-sized hospitals, due to the need for automation in that market segment, particularly in the U.S."
"For Galileo, our high volume instrument, we continue to expect to generate 50 to 70 orders in fiscal 2010, with orders in the U.S. and Canada being lower until the introduction of our next generation automated instrument, the Galileo Neo(TM)," stated Dr. De Chirico. "We continue to expect to launch the Neo in the first calendar quarter of 2010."
Fiscal 2010 Financial Guidance
The Company continues to expect fiscal 2010 consolidated revenue in the range of $322 million to $332 million and consolidated gross margins in the range of 70.0% to 71.5%. The Company's Quality Process Improvement Project is included in cost of goods sold. The Company continues to expect expenses related to the project in fiscal 2010 to be in the range of $4.0 million to $4.5 million.
The Company continues to expect diluted earnings per share to be in the range of $1.10 to $1.17 for fiscal 2010, which includes the approximately $0.04 per share impact, net of tax, related to the Quality Process Improvement Project. The Company's fiscal 2010 guidance also includes a full year of BioArray expenses. BioArray was acquired on August 4, 2008.
The Company also announced today that it repurchased approximately 350,000 shares of its stock during the first fiscal quarter of 2010 for a total of approximately $6.0 million. During August 2009, the Company announced an increase of 2 million shares to its stock repurchase program. The total authorization remaining under the stock repurchase program is approximately 2.5 million shares as of August 31, 2009.
Immucor, Inc. will host a conference call Friday, October 2, 2009 at 8:30 AM (Eastern Time) to review these results. To participate in the telephone conference call, dial 1-888-324-9321 (Passcode: BLUD). The Company will also provide a live audio broadcast of the call via webcast. The webcast can be accessed at www.immucor.com in the "About Us - Investor Information" section by selecting the webcast link. For those unable to listen to the live broadcast of the call, a replay will be available shortly after completion of the call and will be archived on Immucor's website for approximately 60 days. Additionally, a replay of the call will be available for one week beginning at noon on October 2, 2009 by calling 1-866-403-7112 (Passcode: 2583).
Founded in 1982, Immucor manufactures and sells a complete line of reagents and systems used by hospitals, reference laboratories and donor centers to detect and identify certain properties of the cell and serum components of blood prior to transfusion. Immucor markets a complete family of automated instrumentation for all of its market segments. For more information on Immucor, please visit our website at www.immucor.com.
Safe Harbor Statement
This press release contains statements that are "forward-looking statements" as that term is defined under federal securities laws. Forward-looking statements contained in this press release include the intent, belief or current expectations of the Company and members of its management team with respect to the Company's future business operations as well as the assumptions upon which such statements are based. Forward-looking statements include specifically, but are not limited to: fiscal 2010 revenue projections, gross margin projections, fully diluted earnings per share projections; Quality Process Improvement Project projections, including projected expenses and completion date; and instrument order projections. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. In addition, results for one fiscal quarter are not necessarily indicative of results for any future period. Factors that could cause actual results to differ materially from those expressed in any forward-looking statement include, but are not limited to: the outcome and costs associated with the Company's Quality Process Improvement Project; the outcome of the administrative action ("notice of intent to revoke our biological license") received from the Food and Drug Administration ("FDA"); customer reaction to the FDA action and the subsequent impact on the business; lower than expected demand for the Company's instruments; the decision of customers to defer capital spending; the unexpected change in the mix of instruments being purchased instead of acquired through other means, which could significantly change costs recognized in the period; the inability of customers to efficiently integrate the Company's instruments into their blood banking operations; increased competition in the sale of instruments and reagents, particularly in the United States; unanticipated operational problems that result in non-compliance with FDA regulations; the failure to effectively integrate BioArray operations into the Company's overall operations; product development obstacles including obstacles related to the development of the Galileo Neo as well as the next generation automated instrument for the molecular immunohematology products; regulatory obstacles including obstacles in securing regulatory approval of the molecular immunohematology products; the inability to hire and retain, and the unexpected loss of, key managers; changes in interest rates; fluctuations in foreign currency conversion rates; the strengthening of the U.S. Dollar versus any of the functional currencies in which the Company operates and its adverse impact on reported results; the inability of the Company's Japanese, French and United Kingdom subsidiaries to attain expected revenue, gross margin and net income levels; the outcome of any legal claims or regulatory investigations known or unknown, including the ongoing investigations by the Department of Justice and the Federal Trade Commission, and the related customer and shareholder lawsuits; the Company's inability to protect its intellectual property or its infringement of the intellectual property of others; lower than expected market acceptance of the molecular immunohematology products; the unexpected application of different accounting rules; general economic conditions; and adverse developments with respect to the operation or performance of the Company, its products and its affiliates or the market price of its common stock. Additional factors that could cause actual results to differ materially from those contemplated within this Press Release can be found in the Company's Risk Factor disclosures in its Form 10-Q for the quarter ended August 31, 2009 and its Form 10-K for the year ended May 31, 2009. Investors are cautioned not to place undue reliance on any forward-looking statements. Immucor assumes no obligation to update any forward-looking statements.
IMMUCOR, INC. CONDENSED CONSOLIDATED STATEMENTS OF INCOME (unaudited, in thousands except per share data) Three Months Ended ------------------ August 31, August 31, 2009 2008 ---- ---- NET SALES $83,071 $73,176 COST OF SALES 23,382 19,751 ------ ------ GROSS PROFIT 59,689 53,425 OPERATING EXPENSES Research and development 3,823 1,880 Selling and marketing 9,464 9,469 Distribution 3,506 3,468 General and administrative 8,487 7,458 Amortization expense and other 1,067 525 ----- --- Total operating expenses 26,347 22,800 ------ ------ INCOME FROM OPERATIONS 33,342 30,625 NON-OPERATING INCOME (EXPENSE) Interest income 190 794 Interest expense (5) (127) Other, net 30 (420) -- ---- Total non-operating income (expense) 215 247 --- --- INCOME BEFORE INCOME TAXES 33,557 30,872 PROVISION FOR INCOME TAXES 12,224 10,916 ------ ------ NET INCOME $21,333 $19,956 ======= ======= Earnings per share: Per common share - basic $0.30 $0.28 ===== ===== Per common share - diluted $0.30 $0.28 ===== ===== Weighted average shares outstanding: Basic 70,397 70,268 ====== ====== Diluted 70,883 71,210 ====== ======
IMMUCOR, INC. SELECTED CONDENSED CONSOLIDATED BALANCE SHEET ITEMS (Unaudited, in thousands) August 31, May 31, 2009 2009 ---- ---- Cash $152,489 $136,461 Accounts receivable - trade 56,915 57,017 Inventory 41,450 38,256 Total current assets 264,600 244,850 Property and equipment - net 46,587 43,461 Total assets 473,332 451,340 Accounts payable 11,405 9,344 Deferred revenue, current portion 11,305 11,222 Total current liabilities 57,539 52,288 Deferred revenue, long-term portion 9,714 10,871 Other liabilities 3,581 3,603 Shareholders' equity 402,498 384,578
IMMUCOR, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited, in thousands) Quarters Ended -------------- August 31, August 31, 2009 2008 ---- ---- OPERATING ACTIVITIES: Net income $ 21,333 $ 19,956 Adjustments to reconcile net income to net cash provided by operating activities: Depreciation and amortization 3,927 2,867 Share-based compensation expense 1,351 1,193 Deferred income taxes 107 - Excess tax benefit from share-based compensation (167) (2,957) Other 73 362 Changes in operating assets and liabilities, net of effects from acquired companies (2,097) 139 ------ ------ Cash provided by operating activities 24,527 21,560 INVESTING ACTIVITIES: Purchases of property and equipment (3,552) (1,839) Acquisition of businesses, net of cash acquired - (108,230) ------ ------ Cash used in investing activities (3,552) (110,069) FINANCING ACTIVITIES: Repayments of long-term debt and liabilities - (249) Repurchase of common stock (6,185) (961) Proceeds from exercise of stock options - 2,268 Excess tax benefit from share-based compensation 167 2,957 ------ ------ Cash (used in) provided by financing activities (6,018) 4,015 EFFECT OF EXCHANGE RATES ON CASH AND CASH EQUIVALENTS 1,071 (1,442) ------ ------ INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS 16,028 (85,936) CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD 136,461 175,056 ------ ------ CASH AND CASH EQUIVALENTS AT END OF PERIOD$ 152,489 $ 89,120 ====== ======
SOURCE Immucor, Inc.
|SOURCE Immucor, Inc.|
Copyright©2009 PR Newswire.
All rights reserved